A Critical Pathway for Outpatient Treatment of CAPD Peritonitis

Abstract

Get full access to this article

View all access options for this article.

References

Ireson

C.L.

Critical pathways: Effectiveness in achieving patient outcomes.

J Nurs Adm 1997; 27: 16–23.

Shane

Take the first step on the critical pathway.

Am J Health Syst Pharm 1995; 52: 1051–3.

Kirk

J.K.

, Michael

K.A.

, Markowsky

S.J.

, Restino

M.R.

, Zarowitz

B.J.

Critical pathways: The time is here for pharmacist involvement.

Pharmacotherapy 1996; 16: 723–33.

Ibarra

, Titler

M.G.

, Reiter

R.C.

Issues in the development and implementation of clinical pathways.

AACN Clin Issues 1996; 7: 436–47.

Keane

W.F.

, Alexander

S.R.

, Bailie

G.R.

, Boeschoten

, Gokal

, Gopler

T.A.

Peritoneal dialysis-related peritonitis treatment recommendations: 1996 update.

Perit Dial Int 1996; 16: 557–73.

Bernardini

, Piraino

, Holley

, Johnston

J.R.

, Lutes

A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin.

Am J Kidney Dis 1996; 27: 695–700.

Thodis

, Bhaskaran

, Pasadakis

, Bargman

J.M.

, Vas

S.I.

, Oreopoulos

D.G.

Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site.

Perit Dial Int 1998; 18: 261–70.